Comparative Analysis of National Drug Policies - Second Workshop Geneva, 10-13 June 1996 - EDM Research Series No. 025
(1997; 175 pages) Ver el documento en el formato PDF
Índice de contenido
Ver el documentoExecutive summary
Ver el documentoI. Introduction
Abrir esta carpeta y ver su contenidoII. Background on the research project
Abrir esta carpeta y ver su contenidoIII. Second workshop
Abrir esta carpeta y ver su contenidoIV. Preliminary findings
Abrir esta carpeta y ver su contenidoV. Conclusions of the workshop and follow-up plans
Abrir esta carpeta y ver su contenidoAnnex 1: Research proposal
Ver el documentoAnnex 2: List of participants
Ver el documentoAnnex 3: Agenda
Ver el documentoAnnex 4: Questionnaire on NDP performance assessment
Cerrar esta carpetaAnnex 5: Achievements of the national drug policies in the 12 countries
Ver el documentoBulgaria
Ver el documentoChad
Ver el documentoColombia
Ver el documentoGuinea
Ver el documentoIndia
Ver el documentoMali
Ver el documentoPhilippines
Ver el documentoSri Lanka
Ver el documentoThailand
Ver el documentoViet Nam
Ver el documentoZambia
Ver el documentoZimbabwe
Ver el documentoAnnex 6: Consolidated tables
Ver el documentoOther documents in the DAP Research Series
 

Annex 5: Achievements of the national drug policies in the 12 countries

This annex contains a one-page table for each country which used the NDP indicators for assessing its national drug policy, namely Bulgaria, Chad, Colombia, Guinea, India, Mali, Philippines, Sri Lanka, Thailand, Viet Nam, Zambia and Zimbabwe.

Each page contains rated information on:

1. The achievement of the NDP in relation to the four objectives: availability of essential drugs, accessibility of essential drugs, quality of drugs, rational use of drugs.

2. The level of implementation of each key component of the NDP: legislation and regulation, essential drugs selection and drug registration, drug allocation in the health budget/public sector financing policy, public sector procurement procedures, public sector distribution and logistics, pricing policy, information and continuing education on drug use (structure and process).

The rating was done by the teams during the workshop on the basis of the data collected in each country. It used both calculation of averages and judgment related to the relative importance of the various indicators in each subgroup. It was refined later in DAP once new and more accurate data were sent by the countries (see Annex 6).

It should however be seen as tentative and is provided in this annex as an example of what can be achieved with the results of an indicator exercise

Ir a la sección anterior Ir a la siguiente sección
 

Última actualización: le 3 mayo 2013